Get to know the man behind a Microsoft co-founder's exploration of the brain; Mitsubishi finds software to track drug safety events;

> As interpreting DNA sequencing data becomes a focus in biotech research, Complete Genomics ($GNOM) and Ingenuity Systems plan to roll up their technologies to provide a more complete combined service to sequencing customers. Complete Genomics, which has struggled and announced major layoffs recently, touts that the company offers the most accurate sequencing data in the industry. For its part, Ingenuity Systems provides software that identifies and analyzes variants in sequencing data, shedding light on disease-associated abnormalities in the DNA code. Release

> Histogenics, a regenerative medicine outfit, has chosen image analysis software from ImageIQ for its Phase III trial of its bioengineered implant. Release

> Transgenomic has tapped the Medical College of Wisconsin for gene-sequencing and bioinformatics capabilities for one of the company's disease diagnostics. Item

> Learn more about Allan Jones, the man behind Microsoft ($MSFT) co-founder Paul Allen's massive effort to map the brain and understand neurological ailments. Xconomy article

> Japan-based drugmaker Mitsubishi Tanabe Pharma has turned on new software from ArisGlobal for tracking drug and clinical safety. Release

And Finally… In case you missed it, the European Medicines Agency has decided to open up large amounts of industry-generated clinical data to researchers, much to the chagrin of pharma companies. Reuters article

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.